Clinical trials: Hematologic Disease
Acute Myelocytic Leukemia
Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia
This is an open, single-arm, phase I clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting CD123 in the treatment of Acute Myelocytic Leukemia.
- Trial name
- NCT03796390
- Testing
- CD123 CAR-T cells
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Poverty, Social Determinants of Health
Mobile-based Social Services Screening and Referral Tool in an Pediatric Emergency Department
This study will determine the feasibility and effectiveness of using a mobile-based social services screening and referral tool in an urban pediatric Emergency Department (ED).
- Conditions
- Poverty, Social Determinants of Health, Mobile Applications, Pediatric ALL
- Trial name
- NCT03562910
- Testing
- HelpSteps application
- Where
- United States
- Volunteers
- 266 people, healthy volunteers welcome
- Sponsor
- Boston Children's Hospital
Hematopoietic Cell Transplantation Recipient, Plasma Cell Myeloma
Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
This phase II trial studies how well elotuzumab works when given with lenalidomide as maintenance therapy after transplant in patients with newly diagnosed multiple myeloma who underwent transplant using their own stem cells…
- Trial name
- NCT02420860
- Testing
- Elotuzumab, Lenalidomide, Questionnaire Administration
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- M.D. Anderson Cancer Center
Iron-deficiency Anemia
EHR-based Patient Identification and Panel Management of Patients With Iron Deficiency Anemia
The objective is to determine if a set of clinical supports that includes computer-assisted identification, an EHR registry, facilitated GI referral, and an EHR tool for documentation improves the timely referral and completion…
- Trial name
- NCT05365308
- Testing
- Clinical supports
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Northwestern University
Diabetes, Anemia
A Study to Compare Analytes in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
This study will involve an investigational device, the Seventh Sense Biosystems TAP20-C. The TAP20-C device collects small amounts of blood from the forearm which can then be used for blood testing.
- Trial name
- NCT01786408
- Testing
- TAP20-C, SAFE-T-FILL CAPILLARY BLOOD COLLECTION SYSTEM
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Seventh Sense Biosystems
Hereditary Hemorrhagic Telangiectasia, Pulmonary Arterial Hypertension
DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia
This is a Phase 1/2, randomized, double-blind, placebo-controlled, first-in-human study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of subcutaneously administered DIAG723 in adult patients with…
- Trial name
- DIAMOND (NCT07623525)
- Testing
- DIAG723
- Where
- 11 sites in Australia, Canada and 1 more
- Volunteers
- 93 people
- Sponsor
- Diagonal Therapeutics, Inc.
Severe Thalassemia
Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia
This study is being done to determine if blood cell transplants, with either bone marrow or cord blood from unrelated donors, are effective in children with severe thalassemia and if this treatment approach has acceptable risks…
- Trial name
- URTH (NCT01005576)
- Testing
- Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan
- Where
- 18 sites in United States
- Volunteers
- 21 people
- Sponsor
- Washington University School of Medicine
T-cell-prolymphocytic Leukemia
Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)
Study hypothesis: Simultaneous FMC-Alemtuzumab administration followed by Alemtuzumab maintenance therapy in patients with T-PLL is feasible, safe and efficient.
- Trial name
- NCT01186640
- Testing
- Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab, Alemtuzumab
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- German CLL Study Group
Relapsed Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome
Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
This phase I trial tests the safety, side effects, and best dose of eltanexor in combination with venetoclax for the treatment of patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has come back…
- Conditions
- Relapsed Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT06399640
- Testing
- Eltanexor, Venetoclax, Bone Marrow Aspiration and Biopsy
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Chronic Lymphocytic Leukemia, B-cell Lymphomas
Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas
The Primary Objective is to evaluate the safety and tolerability of multiple dose oral administration of DTRMWXHS-12 capsule in patients with B-cell lymphoma.
- Trial name
- NCT02891590
- Testing
- DTRMWXHS-12
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Zhejiang DTRM Biopharma
Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma
A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies
The purpose of this study is to determine the side effects and antitumor response of patients with lymphoid malignancies to Deoxycoformycin (DCF)/Pentostatin.
- Conditions
- Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT00038025
- Testing
- Deoxycoformycin (DCF)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Leukaemia, Lymphocytic, Chronic
Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy
The purpose of this study was to determine if maintenance therapy with ofatumumab would prolong remission in patients with CLL who have responded to second or third line treatment.
- Trial name
- PROLONG (NCT01039376)
- Testing
- Ofatumumab, Observation
- Where
- 203 sites in United States, Argentina and 23 more
- Volunteers
- 480 people
- Sponsor
- Novartis Pharmaceuticals
Depression, Hemodialysis Complication
Intravenous Iron May Increase Depression Among Hemodialysis Patients
the aim of this study is to assess whether increased ferritin after intravenous iron therapy will lead to increased prevalence of major depression among treated patients.
- Conditions
- Depression, Hemodialysis Complication, Iron Deficiency Anemia
- Trial name
- NCT03157050
- Testing
- Intravenous iron therapy
- Volunteers
- 112 people
- Sponsor
- Benha University
Anemia in Chronic Kidney Disease in Non-dialysis Patients
Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa
The primary objective of this study was to evaluate the efficacy of roxadustat compared to darbepoetin alfa in the treatment of anemia in nondialysis-dependent chronic kidney disease (NDD CKD) participants.
- Trial name
- Dolomites (NCT02021318)
- Testing
- Roxadustat, Darbepoetin alfa
- Where
- 125 sites in Austria, Belarus and 24 more
- Volunteers
- 616 people
- Sponsor
- Astellas Pharma Europe B.V.
Lymphoma
Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Trial name
- NCT00003143
- Testing
- Amifostine, DHAP
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Acute Myeloblastic Leukaemia
Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years
To reproduce or to improve the index of complete responses of protocol LMA-91 with a similar protocol, decreasing the dose of Idarubicin to try to reduce the deaths in induction
- Trial name
- NCT00464217
- Testing
- ARA-C, Idarubicin, Leucomax
- Where
- 24 sites in Spain
- Volunteers
- 100 people
- Sponsor
- PETHEMA Foundation
Leukemia
Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML
RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00871689
- Testing
- aldesleukin, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Hemophilia A
A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A
This study is for young children with severe hemophilia A who have previously not been treated with BAX855 or other FVIII concentrates. The main aim of the study is to check for side effects from treatment with BAX855.
- Trial name
- NCT02615691
- Testing
- PEGylated Recombinant Factor VIII, ITI
- Where
- 91 sites in United States, Austria and 21 more
- Volunteers
- 120 people
- Sponsor
- Baxalta now part of Shire
Chronic Lung Disease, Chronic Obstructive Pulmonary Disease
Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise
This study aims to more accurately assess cardiac function, ventilation and exercise capacity in a non-invasive fashion, and to better characterize exercise intolerance in the setting of three populations of individuals with…
- Conditions
- Chronic Lung Disease, Chronic Obstructive Pulmonary Disease, Acute Lymphoblastic Leukemia, Heart Transplant
- Trial name
- FLASHLITE (NCT05025774)
- Testing
- Physical activity
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Myelodysplastic Syndromes (MDS), Acute Myelogenous Leukemia (AML)
Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse
The purpose of this study is to learn if 5'-Azacitidine will help to lower the risk of the disease coming back after a stem cell transplant in patients with MDS and AML.
- Trial name
- NCT01995578
- Testing
- low dose 5'-azacitidine
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Memorial Sloan Kettering Cancer Center